No Prescription |
 |
 | ||
|
Pulmicort Turbuhaler Generic Budesonide |
|
| ||
No Prescription » Prescription Drugs 13 » Pulmicort Turbuhaler Generic Budesonide Medical Information:Maintenance treatment in persistent asthma. Preventing asthma in adults and children 6 years of age or older. It may also be used in patients who require oral corticosteroid medicine. It is not used to relieve an asthma attack.Pulmicort (budesonide) is one of the worldÆs leading asthma medicines. It is an inhaled anti-inflammatory glucocorticosteroid for initiation and maintenance treatment of bronchial asthma in infants children and adults. In some countries Pulmicort is also indicated for the treatment of Chronic Obstructive Pulmonary Disease (COPD). Buy Pulmicort Turbuhaler Generic Budesonide and other Prescription Drugs 13 products online at Medstore. 3711
About Pulmicort Turbuhaler Generic Budesonide: Product Type: Prescription Drugs 13 Pulmicort Turbuhaler ( Generic Budesonide ) Pulmicort Turbuhaler (Generic Budesonide) Generic Budesonide 200mcg 200 Dose Generic Budesonide Pulmicort Turbuhaler
View more Prescription Drugs 13 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
